Kei Kunimasa

2.1k total citations
98 papers, 1.4k citations indexed

About

Kei Kunimasa is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Kei Kunimasa has authored 98 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Pulmonary and Respiratory Medicine, 50 papers in Oncology and 26 papers in Molecular Biology. Recurrent topics in Kei Kunimasa's work include Lung Cancer Treatments and Mutations (56 papers), Cancer Genomics and Diagnostics (24 papers) and Lung Cancer Research Studies (16 papers). Kei Kunimasa is often cited by papers focused on Lung Cancer Treatments and Mutations (56 papers), Cancer Genomics and Diagnostics (24 papers) and Lung Cancer Research Studies (16 papers). Kei Kunimasa collaborates with scholars based in Japan, United States and Netherlands. Kei Kunimasa's co-authors include Kazumi Nishino, Motohiro Tamiya, Takako Inoue, Tadashi Ishida, Toru Kumagai, Taichiro Goto, Hiroshige Yoshioka, Fumio Imamura, Masahiro Iwasaku and Akihiro Nishiyama and has published in prestigious journals such as Nature, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Kei Kunimasa

86 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kei Kunimasa Japan 19 860 786 352 251 100 98 1.4k
Ken Suzawa Japan 19 565 0.7× 504 0.6× 483 1.4× 282 1.1× 57 0.6× 80 1.1k
Akinobu Yoshimura Japan 22 695 0.8× 553 0.7× 704 2.0× 235 0.9× 57 0.6× 69 1.5k
Runsen Jin China 19 456 0.5× 410 0.5× 520 1.5× 259 1.0× 124 1.2× 54 1.1k
Julio Astudillo Spain 14 624 0.7× 482 0.6× 475 1.3× 149 0.6× 86 0.9× 28 1.2k
Esther Zamora Spain 10 576 0.7× 756 1.0× 203 0.6× 277 1.1× 76 0.8× 22 1.0k
Toshio Fujino Japan 16 563 0.7× 420 0.5× 402 1.1× 142 0.6× 59 0.6× 54 975
Shejuan An China 16 722 0.8× 601 0.8× 808 2.3× 400 1.6× 234 2.3× 35 1.5k
Jae Soo Koh South Korea 18 461 0.5× 388 0.5× 401 1.1× 187 0.7× 38 0.4× 71 1.1k
Kuan‐Yu Chen Taiwan 21 579 0.7× 513 0.7× 314 0.9× 163 0.6× 69 0.7× 39 1.1k
Zuli Yang China 18 297 0.3× 290 0.4× 442 1.3× 224 0.9× 96 1.0× 44 963

Countries citing papers authored by Kei Kunimasa

Since Specialization
Citations

This map shows the geographic impact of Kei Kunimasa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kei Kunimasa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kei Kunimasa more than expected).

Fields of papers citing papers by Kei Kunimasa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kei Kunimasa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kei Kunimasa. The network helps show where Kei Kunimasa may publish in the future.

Co-authorship network of co-authors of Kei Kunimasa

This figure shows the co-authorship network connecting the top 25 collaborators of Kei Kunimasa. A scholar is included among the top collaborators of Kei Kunimasa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kei Kunimasa. Kei Kunimasa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kunimasa, Kei, et al.. (2025). Driver mutation detected in cerebrospinal fluid despite negative liquid biopsy results. Discover Oncology. 16(1). 145–145.
2.
3.
Nakabori, Tasuku, Kei Kunimasa, Kaori Mukai, et al.. (2024). Feasibility of atezolizumab and bevacizumab combination regimens in patients with hepatocellular carcinoma and lung cancer taking direct oral anticoagulants. Cancer Medicine. 13(12). e7430–e7430. 1 indexed citations
4.
Inoue, Takako, Takashi Akazawa, Kei Kunimasa, et al.. (2024). Potent CTLs can be induced against tumor cells in an environment of lower levels of systemic MFG‐E8. Cancer Science. 115(4). 1114–1128. 3 indexed citations
5.
Kunimasa, Kei, Motohiro Tamiya, Takako Inoue, et al.. (2024). Clinical application of the Lung Cancer Compact PanelTM using various types of cytological specimens in patients with lung cancer. Lung Cancer. 189. 107498–107498. 4 indexed citations
6.
Kitagawa, Shingo, Yoshitaka Zenke, Kiyotaka Yoh, et al.. (2023). 236TiP Large-scale prospective observational study to develop a liquid-based detection system of minimal residual disease (MRD): LC-SCRUM-MRD. Annals of Oncology. 34. S275–S276. 1 indexed citations
7.
Zenke, Yoshitaka, Kiyotaka Yoh, Shingo Kitagawa, et al.. (2023). 1282P Concordance of PD-L1 expression between biopsy and matched surgical specimen in early-stage non-small cell lung cancer: LC-SCRUM-Advantage/MRD. Annals of Oncology. 34. S740–S741. 1 indexed citations
8.
Kunimasa, Kei, Shingo Matsumoto, Takahisa Kawamura, et al.. (2023). Clinical application of the AMOY 9-in-1 panel to lung cancer patients. Lung Cancer. 179. 107190–107190. 20 indexed citations
9.
Yamai, Takuo, Kenji Ikezawa, Naotoshi Sugimoto, et al.. (2023). Utility of Comprehensive Genomic Profiling Tests for Patients with Incurable Pancreatic Cancer in Clinical Practice. Cancers. 15(3). 970–970. 13 indexed citations
10.
Yoh, Kiyotaka, Yoshitaka Zenke, Shingo Kitagawa, et al.. (2023). 1276P Genomic screening by multi-gene assay for perioperative targeted therapy in patients with early-stage non-small cell lung cancer: LC-SCRUM-Advantage/MRD. Annals of Oncology. 34. S737–S737. 1 indexed citations
11.
Kunimasa, Kei, Yosuke Hirotsu, Kenji Amemiya, et al.. (2023). Genetic dissection of intratumor heterogeneity of PD‐L1 expression in EGFR‐mutated lung adenocarcinoma. Thoracic Cancer. 14(22). 2210–2215. 3 indexed citations
12.
Hayashi, Hideyuki, Kei Kunimasa, Shigeki Tanishima, et al.. (2023). Germline BRCA2 variant with low variant allele frequency detected in tumor‐only comprehensive genomic profiling. Cancer Science. 115(2). 682–686. 5 indexed citations
13.
Ohkawa, Yuki, Yasuhiko Kizuka, Kei Kunimasa, et al.. (2023). A highly specific antibody against the core fucose of the N-glycan in IgG identifies the pulmonary diseases and its regulation by CCL2. Journal of Biological Chemistry. 299(12). 105365–105365. 8 indexed citations
14.
Kunimasa, Kei, Kazumi Nishino, Yoshiharu Sato, et al.. (2022). Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC. Scientific Reports. 12(1). 13544–13544. 5 indexed citations
15.
Kunimasa, Kei, Toru Oka, Satoshi Hara, et al.. (2020). Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction. Lung Cancer. 153. 186–192. 24 indexed citations
16.
Kunimasa, Kei, Toru Oka, Makiko Oboshi, et al.. (2020). Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With Osimertinib. JACC CardioOncology. 2(1). 1–10. 58 indexed citations
17.
Goto, Taichiro, Kei Kunimasa, Yosuke Hirotsu, et al.. (2020). Association of Mutation Profiles with Postoperative Survival in Patients with Non–Small Cell Lung Cancer. Cancers. 12(11). 3472–3472. 8 indexed citations
18.
Inoue, Takako, Tatsuya Nishikawa, Kei Kunimasa, et al.. (2020). Infectious pericarditis caused by Gemella sanguinis induced by Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA): A case report. Respiratory Medicine Case Reports. 30. 101057–101057. 6 indexed citations
19.
Kumagai, Toru, Yasuhiko Tomita, Shin‐ichi Nakatsuka, et al.. (2018). HER3 expression is enhanced during progression of lung adenocarcinoma without EGFR mutation from stage 0 to IA1. Thoracic Cancer. 9(4). 466–471. 9 indexed citations
20.
Kunimasa, Kei, Mika Saigusa, Tsuyoshi Yamada, & Tadashi Ishida. (2012). Reversible lesion in the splenium of the corpus callosum associated with Legionnaires’ pneumonia. BMJ Case Reports. 2012. bcr1120115096–bcr1120115096. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ken Suzawa Breakdown of academic impact, for papers by Akinobu Yoshimura Breakdown of academic impact, for papers by Runsen Jin Breakdown of academic impact, for papers by Julio Astudillo Breakdown of academic impact, for papers by Esther Zamora Breakdown of academic impact, for papers by Toshio Fujino Breakdown of academic impact, for papers by Shejuan An Breakdown of academic impact, for papers by Jae Soo Koh Breakdown of academic impact, for papers by Kuan‐Yu Chen Breakdown of academic impact, for papers by Zuli Yang
Rankless by CCL
2026